• 1. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 2. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 3. An insight into the origin of room-temperature ferromagnetism in SnO2 and Mn-doped SnO2 quantum dots: an experimental and DFT approach?
  Dhamodaran Manikandan,S. Amirthapandian,I. S. Zhidkov,A. I. Kukharenko,S. O. Cholakh,Ramaswamy Murugan Phys. Chem. Chem. Phys., 2018,20, 6500-6514
• 4. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 5. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzenesulfonamides

Research Briefing on 4-(morpholine-4-sulfonyl)phenol (CAS: 3077-65-4) in Chemical Biology and Pharmaceutical Applications

4-(morpholine-4-sulfonyl)phenol (CAS: 3077-65-4) is a sulfonamide derivative that has garnered significant attention in recent chemical biology and pharmaceutical research due to its unique structural features and potential therapeutic applications. This compound, characterized by a phenol group linked to a morpholine ring via a sulfonyl bridge, exhibits versatile reactivity and has been explored as a key intermediate or active moiety in drug discovery programs. Recent studies have highlighted its role in modulating various biological targets, particularly in the context of kinase inhibition and enzyme regulation.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 4-(morpholine-4-sulfonyl)phenol serves as a crucial scaffold for developing selective protein kinase inhibitors. The research team utilized structure-activity relationship (SAR) analysis to optimize the compound's interactions with ATP-binding sites, achieving nanomolar potency against several cancer-related kinases while maintaining excellent selectivity profiles. Molecular docking studies revealed that the morpholine sulfonyl group participates in critical hydrogen bonding interactions with key amino acid residues in the kinase domain.

In pharmaceutical formulation research, 4-(morpholine-4-sulfonyl)phenol has shown promise as a stabilizer for oxidation-prone active pharmaceutical ingredients (APIs). A 2024 publication in Molecular Pharmaceutics reported its exceptional radical scavenging properties when incorporated into solid dispersion systems. The compound's phenol group effectively quenches free radicals, while the morpholine sulfonyl moiety enhances the physical stability of amorphous drug formulations, addressing a major challenge in the development of poorly water-soluble drugs.

Recent synthetic methodology developments have significantly improved access to 4-(morpholine-4-sulfonyl)phenol derivatives. A breakthrough described in Organic Letters (2023) presented a novel photocatalytic sulfonylation protocol that enables the efficient introduction of the morpholine sulfonyl group to phenolic substrates under mild conditions. This green chemistry approach achieves yields exceeding 85% while avoiding traditional harsh reagents, making it particularly valuable for late-stage functionalization in drug discovery campaigns.

The compound's ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties were systematically evaluated in a 2024 study published in European Journal of Pharmaceutical Sciences. Researchers found that 4-(morpholine-4-sulfonyl)phenol exhibits favorable pharmacokinetic characteristics, including good membrane permeability (Papp > 15 × 10^-6 cm/s in Caco-2 assays) and moderate plasma protein binding (≈75%). Notably, the compound demonstrated minimal inhibition of major cytochrome P450 enzymes, suggesting low potential for drug-drug interactions in therapeutic applications.

Emerging applications in chemical biology have expanded the utility of 4-(morpholine-4-sulfonyl)phenol beyond traditional drug discovery. A recent Nature Chemical Biology publication (2024) highlighted its use as a versatile warhead in targeted protein degradation strategies. By conjugating the phenol group to E3 ligase-recruiting moieties, researchers developed proteolysis-targeting chimeras (PROTACs) that effectively degrade challenging targets, including transcription factors previously considered "undruggable." The morpholine sulfonyl group in these constructs was found to enhance cellular permeability and solubility.

Ongoing clinical investigations have brought 4-(morpholine-4-sulfonyl)phenol derivatives into translational research. Current Phase I trials (NCT identifier: NCT05678934) are evaluating a lead compound containing this scaffold as a potential treatment for resistant non-small cell lung cancer. Preliminary results presented at the 2024 AACR Annual Meeting showed promising tumor response rates (ORR: 38%) with manageable toxicity profiles, supporting further clinical development.

• 70682-63-2(2-Naphthalenesulfonamide,6-hydroxy-N-(2-hydroxyethyl)-N-methyl-)
• 391243-72-4(Benzenesulfonamide, N,N-bis(2-hydroxyethyl)-4-methoxy-)
• 882848-29-5(Benzenesulfonamide, 4-[2-(diethylamino)ethoxy]-N,N-diethyl-,monohydrochloride)
• 55619-44-8(4-(morpholine-4-sulfonyl)benzene-1-sulfonamide)
• 656804-36-3(Morpholine, 4-[(3,4-dihydroxyphenyl)sulfonyl]-)
• 391243-85-9(Benzenesulfonamide,N-[2-(ethenyloxy)ethyl]-N-(2-hydroxyethyl)-4-methoxy-)
• 874754-28-6(4-[4-(2-bromoethoxy)benzenesulfonyl]morpholine)
• 5318-93-4(Phosphorodithioic acid,O-cyclohexyl O-ethyl S-[(ethylthio)methyl] ester (7CI,8CI))
• 6339-26-0(4-Tosylmorpholine)
• 5033-21-6(4-(phenylsulfonyl)morpholine)